A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
CompletedOBSERVATIONAL
Enrollment
89
Participants
Timeline
Start Date
June 7, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
Conditions
Chronic Lymphocytic Leukemia
Trial Locations (1)
277-8577
National Cancer Center Hospital East /ID# 265970, Kashiwa-shi